key: cord-0330743-dd7j96ty authors: Yang, Ning; Garzia, Aitor; Meyer, Cindy; Tuschl, Thomas; Merghoub, Taha; Wolchok, Jedd D.; Deng, Liang title: Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathway date: 2021-07-26 journal: bioRxiv DOI: 10.1101/2021.07.24.453449 sha: cf613dcfc6d3fddbf325f1991487c4780e1c85b1 doc_id: 330743 cord_uid: dd7j96ty Background Protein or peptide-based subunit vaccines are promising platforms for combating human cancers and infectious diseases. However, one primary concern regarding subunit vaccines is the relatively weak immune responses induced by proteins or peptides. Therefore, developing novel and effective vaccine adjuvants is critical for the success of subunit vaccines. Modified vaccinia virus (MVA) is a safe and effective vaccine against smallpox and monkeypox. In this study, we explored the potential of heat-inactivated MVA (heat-iMVA) as a novel vaccine adjuvant. Methods We co-administered heat-iMVA with a model antigen, chicken ovalbumin (OVA), either intramuscularly or subcutaneously twice, two weeks apart, and analyzed anti-OVA specific CD8+ and CD4+ T cells in the spleens and skin draining lymph nodes (dLNs) and serum anti-OVA IgG1 and IgG2c antibodies. We also compared the adjuvanticity of heat-iMVA with several known vaccine adjuvants, including complete Freund’s adjuvant (CFA) and AddaVax, an MF59-like preclinical grade nano-emulsion. In addition, we tested whether co-administration of heat-iMVA plus tumor neoantigen peptides or irradiated tumor cells improves antitumor efficacy in a B16-F10 therapeutic vaccination model. Using Stimulator of Interferon Genes (STING) or Batf3-deficient mice, we evaluated the contribution of the STING pathway and Batf3-dependent CD103+/CD8α DCs in heat-iMVA-induced immunity. Results Co-administration of protein- or peptide-based immunogens with heat-iMVA dramatically enhances Th1-biased cellular and humoral immune responses. This adjuvant effect of heat-iMVA is dependent on the STING-mediated cytosolic DNA-sensing pathway, and the antigen-specific CD8+ T cell response requires Batf3-dependent CD103+/CD8α+ dendritic cells (DCs). Heat-iMVA infection of bone marrow-derived DCs (BMDCs) promoted antigen cross-presentation, whereas live MVA infection did not. RNA-seq analyses revealed that heat-iMVA is a more potent activator of the STING pathway than live MVA. Additionally, combining tumor neoantigen peptides or irradiated tumor cells with heat-iMVA delayed tumor growth and extended the median survival in B16-F10 therapeutic vaccination models. Conclusions Heat-iMVA induces type I interferon (IFN) production and antigen cross-presentation via a STING-dependent mechanism in DCs. Co-administration of heat-iMVA with peptide antigen generates strong Th1-biased cellular and humoral immunity. Collectively, our results demonstrate that heat-iMVA is a safe and potent vaccine adjuvant. Background: Protein or peptide-based subunit vaccines are promising platforms for combating 24 human cancers and infectious diseases. However, one primary concern regarding subunit 25 vaccines is the relatively weak immune responses induced by proteins or peptides. Therefore, 26 developing novel and effective vaccine adjuvants is critical for the success of subunit vaccines. 27 Modified vaccinia virus (MVA) is a safe and effective vaccine against smallpox and monkeypox. 28 In this study, we explored the potential of heat-inactivated MVA (heat-iMVA) as a novel vaccine 29 Methods: We co-administered heat-iMVA with a model antigen, chicken ovalbumin (OVA), 31 either intramuscularly or subcutaneously twice, two weeks apart, and analyzed anti-OVA 32 specific CD8 + and CD4 + T cells in the spleens and skin draining lymph nodes (dLNs) and serum 33 anti-OVA IgG1 and IgG2c antibodies. We also compared the adjuvanticity of heat-iMVA with 34 several known vaccine adjuvants, including complete Freund's adjuvant (CFA) and AddaVax, an 35 MF59-like preclinical grade nano-emulsion. In addition, we tested whether co-administration of 36 heat-iMVA plus tumor neoantigen peptides or irradiated tumor cells improves antitumor efficacy 37 in a B16-F10 therapeutic vaccination model. Using Stimulator of Interferon Genes (STING) or 38 Batf3-deficient mice, we evaluated the contribution of the STING pathway and Batf3-dependent 39 CD103 + /CD8a DCs in heat-iMVA-induced immunity. The antibody titer is defined as the dilution in which absorbance is more than 2. Bioanalyzer at the Rockefeller University Genomics Resource Center was used to assess total 211 RNA integrity and quantity. Samples with the RNA integrity number (RIN) > 9.5 were used. 212 Oligo(dT)-selected RNA was converted into cDNA for RNA sequencing using the Illumina 213 TruSeq RNA Sample Preparation Kit v2 according to the instructions of the manufacturer and 214 sequenced on an Illumina HiSeq 2500 platform using 100 nt single-end sequencing. Reads were 215 aligned against the mouse genome (Gencode, GRCm38) plus vaccinia genome (VACV-MVA) 216 using TopHat v2.0.14 (http://tophat.cbcb.umd.edu/). The steps described followed the protocol 217 by Trapnell and colleagues 31 . Cufflinks v2.1.1 (http://cole-trapnell-lab.github.io/cufflinks/) was 218 used for estimation of transcript abundance and differential expression analysis. Unsupervised 219 hierarchical clustering was performed using Euclidean distance and complete linkage for 220 columns (samples) and rows (mRNAs). For clarity, the row dendrograms were removed from the 221 figures. The R packages pheatmap was used for data representation. Gene set enrichment 222 analysis (GSEA) was conducted using the package fgsea with 1000 permutations, with reactome 223 and MSigDB C7 signature sets. figure. 2A and 2B ). Serum IgG1 titers from OVA + CFA-immunized mice were 280 6-fold higher than those in the serum from OVA + heat-iMVA-immunized mice (Fig 2C) , 281 whereas serum IgG2c titers from OVA + CFA-immunized mice were 10-fold lower than those in 282 the serum of OVA + heat-iMVA-immunized mice ( Fig 2D) . These results indicate that co-283 administration of OVA plus Heat-iMVA promotes stronger Th1-biased humoral immunity than 284 OVA plus CFA. for transferring antigens to skin draining LN 42 , we observed that OVA-647 was mostly found in 385 the three types of migratory DCs, including CD11b + , CD103 + , and CD11b -CD103 -DCs, but 386 rarely detected in resident DCs ( figure 6A and 6C ). Co-administration of OVA-647 with heat-387 iMVA increased the percentage of OVA-647 + CD11b + , CD103 + , CD11b -CD103 -, and CD8a + 388 DCs, compared with injection of OVA-647 alone ( figure 6C and 6E) . These results suggest that 389 co-administration of OVA-647 with heat-iMVA enhances the capacity of migratory DCs to 390 transport phagocytosed antigen to the skin dLNs and facilitates the antigen transfer from 391 migratory DCs to CD8a + DCs, a lymphoid-resident DC population critical for antigen cross-392 presentation. Migratory DCs expressed higher levels of CD86 maturation marker than resident 393 DCs ( figure 6B and 6D ). Intradermal vaccination with OVA plus heat-iMVA induced higher 394 levels of CD86 on resident DCs (CD8 + DC or CD8 -DC) than with OVA alone ( figure 6D and 395 6F). By contrast, heat-iMVA co-administration did not change the maturation status of migratory 396 DCs entering skin draining LNs ( figure 6D and 6F ). Our results indicate that intradermal co-397 administration of heat-iMVA with OVA antigen promotes antigen-carrying migratory DCs 398 trafficking into the skin draining LN and transferring of antigens from migratory DCs to CD8a + 399 DCs and induce resident DC maturation. 400 Using Batf3 -/mice, we also demonstrated that heat-iMVA-boosted antigen-specific 474 CD8 + T cell responses are dependent on cDC1s, also known as CD103 + /CD8a + DCs. However, 475 heat-iMVA-boosted antigen-specific CD4 + T cell responses were not lost in Batf3 -/mice, 476 suggesting that cDC2s, also known as CD11b + DCs, might be responsible for antigen 477 presentation via MHC-II. KastenmÜller et al. investigated the role of Batf3-dependent 478 CD103 + /CD8a DCs in protein-TLR7/8 agonist conjugate and they found that CD8 + T cell 479 responses were significant reduced in Batf3 KO mice, whereas CD4 + T cell responses were not 480 affected 48 . Interestingly, heat-iMVA-boosted antigen-specific antibody responses were not 481 affected in Batf3 -/mice. This finding is consistent with a recent report that migratory CD11b + 482 DCs (cDC2s) are required for priming T follicular helper (Tfh) cells, a subset of CD4 + T cells, 483 for antigen-specific antibody production 49 . 484 485 An increasing body of evidence indicates that STING agonists can function as potent 486 vaccine adjuvants 9 10 36 50-52 . To probe the role of the STING-mediated cytosolic DNA-sensing 487 pathway in heat-iMVA adjuvanticity, we used STING Gt/Gt mice, which lack functional STING 53 . 488 Our results demonstrate that STING contributes to the generation of antigen-specific IFN-g + 489 CD8 + and CD4 + T cells and IgG2c antibody production potentiated by heat-iMVA. Given the 490 essential roles of cDC1 and cDC2 in mediating CD8 + and CD4 + T cell priming, we surmise that 491 STING signaling in cDC1 and cDC2 is important for heat-iMVA-induced immunogenicity. We 492 note three major differences between heat-iMVA and small-molecule chemical STING agonists: 493 (i) heat-iMVA enters cells naturally 24 , whereas chemical STING agonists need lipophilic 494 mediators to facilitate their entry; (ii) heat-inactivated vaccinia can also trigger type I IFN 495 production in pDCs via a TLR7/TLR9/MyD88-dependent pathway 24 26 , whereas chemical 496 STING agonists are specific to the STING pathway; and (iii) heat-iMVA activates other danger 497 signals, including the Absent In Melanoma 2 (AIM2) inflammasome ( 54 and data not shown), 498 which might also be important for heat-iMVA adjuvanticity. Our results showed that SC heat-499 iMVA co-administration with OVA-647 significantly increased OVA-647 + migratory DCs in the 500 dLNs. Interestingly, heat-iMVA also increased OVA-647 + CD8a + DCs in the dLNs. Although 501 migratory DCs in the dLNs exhibited high CD86 expression with or without heat-iMVA as a 502 vaccine adjuvant, heat-iMVA co-delivery resulted in higher expression of CD86 on resident 503 DCs, including both CD8 + DCs and CD8 -DCs. These results suggest that heat-iMVA co-504 administration promotes peripheral DC maturation and migration into dLNs, as well as LN-505 resident DC maturation. We speculate that some heat-iMVA virions (together with OVA-647 + ) 506 might be transported, via the LN conduits, to the LN interior to resident DCs, as demonstrated 507 for subcutaneously injected vaccinia virus or MVA 55 . 508 Limitations of the study include but are limited to the following: (i) vaccination studies 509 were performed in female C57BL/6J mice at 6-8 weeks of age. Potential age, sex, and species 510 bias cannot be excluded; Because the Batf3 and STING-deficient mice are in C57BJ/6J 511 background, we chose this strain for our study; (ii) we did not analyze what cell populations are 512 infected by heat-iMVA after vaccination, because heat-iMVA does not produce viral proteins; 513 we plan to do more sophisticated analyses with immune-activating recombinant MVA 514 expressing fluorescent markers in our future studies; and (iii) we did not explore whether antigen 515 conjugation to heat-iMVA or mixing antigen with Addavax plus heat-iMVA would further 516 enhance immune efficacy in this study. 517 Nörder et al. investigated whether MVA could be used as a vaccine adjuvant, and they 518 found that IM co-administration of MVA and OVA enhances the generation of antigen-specific 519 antibody and T cell responses 56 . MVA is non-replicative in most mammalian cells and heat-520 inactivation makes it safer and more immunogenic. 521 In conclusion, we envision that heat-iMVA can be used as a vaccine adjuvant for 522 neoantigen-based or irradiated whole cell-based cancer vaccines based on its safety and 523 immunogenicity. Heat-iMVA activation of STING signaling contributes to its adjuvanticity and 524 heat-iMVA promotes antigen cross-presentation by Batf3-dependent CD103 + /CD8a + DCs to 525 induce antigen-specific CD8 + T cell responses. Future work will focus on identifying viral 526 inhibitors of the cGAS/STING pathway encoded by the MVA genome and engineering 527 recombinant MVA to improve its immunogenicity and adjuvanticity. 528 BMDCs and analyzed the RNA-seq data. Memorial Sloan Kettering Cancer Center filed a patent 628 application for the Heat-inactivated vaccinia virus as a vaccine immune adjuvant assisted in experimental design and data interpretation Competing Interests Memorial Sloan Kettering Cancer Center filed a patent application for the heat-inactivated 634 are authors on the patent, 635 which has been licensed to IMVAQ Therapeutics He has research support from Bristol Myers Squibb He has patents on applications related to 640 work on oncolytic viral therapy, alpha virus-based vaccine, neoantigen modeling, CD40, GITR Advaxis, Am-gen Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq Honorarium: Esanex. Patents: xenogeneic DNA vaccines alphavirus replicon particles ex-pressing TRP2, MDSC assay, Newcastle disease viruses for 650 cancer therapy, genomic signature to identify responders to ipilimumab in melanoma Personalized RNA mutanome vaccines mobilize 662 poly-specific therapeutic immunity against cancer An immunogenic personal neoantigen vaccine for patients 665 with melanoma Neoantigens in cancer immunotherapy Exploiting the mutanome for tumor vaccination Cancer exome analysis reveals a T-cell-674 dependent mechanism of cancer immunoediting Neoantigen vaccine generates intratumoral T cell 677 responses in phase Ib glioblastoma trial Personal neoantigen vaccines induce persistent memory T 680 cell responses and epitope spreading in patients with melanoma Emerging concepts in the science of vaccine adjuvants Combining STING-based neoantigen-targeted vaccine 687 with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer Natural STING Agonist as an "Ideal" Adjuvant for Cutaneous 691 Vaccination Programming the magnitude and persistence of 694 antibody responses with innate immunity Control of a mucosal challenge and prevention of 697 AIDS by a multiprotein DNA/MVA vaccine Severe acute respiratory syndrome coronavirus spike 700 protein expressed by attenuated vaccinia virus protectively immunizes mice A recombinant vector derived from the host range-704 restricted and highly attenuated MVA strain of vaccinia virus stimulates protective 705 immunity in mice to influenza virus Immunogenicity of a highly attenuated MVA smallpox 708 vaccine and protection against monkeypox Immunization of rhesus macaques with a DNA 711 prime/modified vaccinia virus Ankara boost regimen induces broad simian 712 immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral 713 replication but does not prevent disease progression following challenge with pathogenic 714 Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a 717 Vaccine against Smallpox Clinical development of Modified Vaccinia virus Ankara vaccines Modified Vaccinia Virus Ankara: History, Value in Basic Research, and 723 Current Perspectives for Vaccine Development Modified vaccinia virus Ankara triggers type I IFN production 726 in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-727 sensing pathway Poxviruses and immune evasion Innate immune activation of NFkappaB and its antagonism by 733 poxviruses Lung type II alveolar 736 epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against 737 an acute vaccinia infection in the lungs Intratumoral delivery of inactivated modified vaccinia virus 743 Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent 744 dendritic cells Myxoma virus induces type I interferon production in 747 murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-748 dependent pathway The ARRIVE guidelines 2.0: updated 751 guidelines for reporting animal research Retroviruses pseudotyped with the severe acute 754 respiratory syndrome coronavirus spike protein efficiently infect cells expressing 755 angiotensin-converting enzyme 2 Vaccination with irradiated tumor cells engineered to 758 secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, 759 specific, and long-lasting anti-tumor immunity Phosphatidylinositol 4-kinase IIIbeta is required for severe 762 acute respiratory syndrome coronavirus spike-mediated cell entry Differential gene and transcript expression analysis of 766 RNA-seq experiments with TopHat and Cufflinks Vaccine adjuvants: current state and future trends Safety and immunogenicity of an MF59-adjuvanted 772 spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, 773 placebo-controlled, phase 1 trial The adjuvant MF59 induces ATP release from muscle 776 that potentiates response to vaccination Batf3 deficiency reveals a critical role for 779 CD8alpha+ dendritic cells in cytotoxic T cell immunity Pivotal roles of cGAS-cGAMP signaling in antiviral defense and 782 immune adjuvant effects Simultaneous high-resolution analysis of vaccinia 785 virus and host cell transcriptomes by deep RNA sequencing The dendritic cell lineage: ontogeny and function of 789 dendritic cells and their subsets in the steady state and the inflamed setting Migratory dendritic cells transfer antigen to a lymph 793 node-resident dendritic cell population for efficient CTL priming Active dissemination of cellular antigens by DCs 797 facilitates CD8(+) T-cell priming in lymph nodes Specialized role of migratory dendritic cells in 800 peripheral tolerance induction Transfer of antigen between migrating and lymph node-803 resident DCs in peripheral T-cell tolerance and immunity Alum adjuvant boosts adaptive immunity by 808 inducing uric acid and activating inflammatory dendritic cells Squalene emulsion-based vaccine adjuvants 811 stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway Intravenous nanoparticle vaccination 814 generates stem-like TCF1(+) neoantigen-specific CD8(+) T cells Efficient Induction of Cytotoxic T Cells by Viral 818 Vector Vaccination Requires STING-Dependent DC Functions Protective T cell immunity in mice 821 following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I 822 IFN, and multiple DC subsets Migratory CD11b(+) conventional 825 dendritic cells induce T follicular helper cell-dependent antibody responses Pulmonary surfactant-biomimetic nanoparticles potentiate 828 heterosubtypic influenza immunity STING activator c-di-GMP enhances the anti-tumor effects of peptide 831 vaccines in melanoma-bearing mice The STING activator c-di-AMP 834 exerts superior adjuvant properties than the formulation poly(I:C)/CpG after 835 subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen 836 targeting to dendritic cells Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon 840 response to Listeria monocytogenes and cyclic dinucleotides AIM2 recognizes cytosolic dsDNA and 843 forms a caspase-1-activating inflammasome with ASC Lymph node conduits transport virions for 846 rapid T cell activation Modified vaccinia virus Ankara exerts potent immune 849 modulatory activities in a murine model We thank the Flow Cytometry Core Facility and Molecular Cytology Core Facility at the Sloan 605Kettering Institute. We also thank the Rockefeller University Genomics Resource Center. We 606 thank Peihong Dai's technical support for BMDC RNA-seq experiments. We also thank 607 Shuaitong Liu and Yi Wang's technical assistance on antigen cross-presentation assay.